Capmatinib

CHEMBL3188267 Phase 4 Disetujui Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

412.4 g/mol

LogP

2.9

Phase

4

A targeted therapy that specifically inhibits the MET receptor tyrosine kinase, which is abnormally activated in certain non-small cell lung cancers due to MET exon 14 skipping mutations. By blocking MET, it suppresses tumor growth and spread in these genetically defined tumors. Peripheral edema, nausea, and fatigue are among the most common side effects.

Berat Molekul

412,4000 g/mol

LogP

2,90

TPSA

85,10 Å²

Lipinski RO5

Lulus

Area Terapeutik

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Struktur 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CNC(=O)c1ccc(-c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2)cc1F

InChI

InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)

Molecular Formula

C23H17FN6O

HBD / HBA

1 / 6

Ikatan yang Dapat Dirotasi

4

Atom Berat

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

A targeted therapy that specifically inhibits the MET receptor tyrosine kinase, which is abnormally activated in certain non-small cell lung cancers due to MET exon 14 skipping mutations. By blocking MET, it suppresses tumor growth and spread in these genetically defined tumors. Peripheral edema, nausea, and fatigue are among the most common side effects.

Yes, Capmatinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3188267. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 25145656. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Mencari informasi yang ramah bagi pasien?

Capmatinib di PillFYI

Struktur

Data Cepat

Rumus: C23H17FN6O
Sinonim: 1

Tautan Eksternal

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.